Epidemiology, Clinical Features, and Prescribing Patterns of Irritable Bowel Syndrome in Taiwan

Yu-Tung Lai, Chung-Yu Chen, Ming-Jong Bair, Yu-Tung Lai, Chung-Yu Chen, Ming-Jong Bair

Abstract

Background: Understanding the prescribing patterns could better inform irritable bowel syndrome (IBS) management and health policy. However, there is no study on prescribing patterns of IBS in Taiwan. This study was conducted to evaluate the epidemiology, clinical features, and prescribing patterns of IBS in Taiwan. Methods: This population-based cross-sectional study was performed by retrieving claim data from National Health Insurance Research Database (NHIRD) between 2011 and 2018 in Taiwan. Patients who were diagnosed with IBS during 2012-2018 and more than 20 years old were included. The annual incidence and prevalence of IBS were estimated. The characteristics and prescribing pattern were evaluated among IBS population. The population with IBS were followed from index date until 1 year after or death. Results: A total of 1691596 patients diagnosed with IBS were identified from 2012 to 2018. The average annual incidence and prevalence of IBS in Taiwan were calculated as 106.54 and 181.75 per 10,000 population. The incidence and prevalence showed a decreasing trend from 2012 to 2018. Hypertension, dyslipidemia, chronic liver disease, peptic ulcer, gastroesophageal reflux disease (GERD), anxiety, and sleep disorder were the prevalent comorbidities in IBS population. At 1 year after IBS diagnosis, the rates of peptic ulcer and GERD; the utilizations of abdominal ultrasonography, upper gastrointestinal (GI) endoscopy, and lower GI endoscopy; the prescribing rate of propulsives, simethicone, antacids, H2-blockers, and proton pump inhibitors significantly increased. Approximately 70% of participants received IBS-related treatment. Antispasmodics was the most frequently prescribed medication class, followed by laxatives and antidiarrheals. Only 48.58% of patients made return visit for IBS at 1 year after IBS diagnosis. Consequently, the proportion of consultation for IBS and the prescribing rates of all medications were decreased considerably after IBS diagnosis. Conclusion: The incidence and prevalence of IBS showed a decreasing trend from 2012 to 2018. More than two-third of patients received treatment for IBS. Antispasmodics was widely used for IBS management. However, patients may have a short symptom duration or receive a short course of IBS-related treatment in Taiwan. These findings provided the whole picture of the epidemiology and prescribing pattern of the IBS population in Taiwan.

Keywords: clinical features; epidemiology; irritable bowel syndrome; pattern; pharmacoepidaemiology.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lai, Chen and Bair.

Figures

FIGURE 1
FIGURE 1
The annual incidence of IBS during 2012–2018.
FIGURE 2
FIGURE 2
The annual prevalence of IBS during 2012–2018.
FIGURE 3
FIGURE 3
The trend in different pharmacological type of prescription.

References

    1. Albillos A., de Gottardi A., Rescigno M. (2020). The Gut-Liver axis in Liver Disease: Pathophysiological Basis for Therapy. J. Hepatol. 72 (3), 558–577. 10.1016/j.jhep.2019.10.003
    1. Bai T., Xia J., Jiang Y., Cao H., Zhao Y., Zhang L., et al. (2017). Comparison of the Rome IV and Rome III Criteria for IBS Diagnosis: A Cross-Sectional Survey. J. Gastroenterol. Hepatol. 32 (5), 1018–1025. 10.1111/jgh.13642
    1. Bayrak M. (2020). Metabolic Syndrome, Depression, and Fibromyalgia Syndrome Prevalence in Patients with Irritable Bowel Syndrome: A Case-Control Study. Medicine (Baltimore) 99 (23), e20577. 10.1097/MD.0000000000020577
    1. Black C. J., Ford A. C. (2020). Global burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors. Nat. Rev. Gastroenterol. Hepatol. 17 (8), 473–486. 10.1038/s41575-020-0286-8
    1. Bonetto S., Fagoonee S., Battaglia E., Grassini M., Saracco G. M., Pellicano R. (2021). Recent Advances in the Treatment of Irritable Bowel Syndrome. Pol. Arch. Intern. Med. 131 (7-8), 709–715. 10.20452/pamw.16067
    1. Chang F. Y., Chen P. H., Wu T. C., Pan W. H., Chang H. Y., Wu S. J., et al. (2012). Prevalence of Functional Gastrointestinal Disorders in Taiwan: Questionnaire-Based Survey for Adults Based on the Rome III Criteria. Asia Pac. J. Clin. Nutr. 21 (4), 594–600.
    1. Chang H. C., Yen A. M., Fann J. C., Chiu S. Y., Liao C. S., Chen H. H., et al. (2015). Irritable Bowel Syndrome and the Incidence of Colorectal Neoplasia: a Prospective Cohort Study with Community-Based Screened Population in Taiwan. Br. J. Cancer 112 (1), 171–176. 10.1038/bjc.2014.575
    1. de Bortoli N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E., et al. (2018). Gastroesophageal Reflux Disease, Functional Dyspepsia and Irritable Bowel Syndrome: Common Overlapping Gastrointestinal Disorders. Ann. Gastroenterol. 31 (6), 639–648. 10.20524/aog.2018.0314
    1. Drossman D. A. (2016). Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 150 (6), 1262–1279. 10.1053/j.gastro.2016.02.032
    1. Ducrotte P., Grimaud J. C., Dapoigny M., Personnic S., O'Mahony V., Andro-Delestrain M. C. (2014). On-demand Treatment with Alverine Citrate/simeticone Compared with Standard Treatments for Irritable Bowel Syndrome: Results of a Randomised Pragmatic Study. Int. J. Clin. Pract. 68 (2), 245–254. 10.1111/ijcp.12333
    1. Ellis R. P., Hsu H. E., Song C., Kuo T. C., Martins B., Siracuse J. J., et al. (2020). Diagnostic Category Prevalence in 3 Classification Systems across the Transition to the International Classification of Diseases, Tenth Revision, Clinical Modification. JAMA Netw. Open 3 (4), e202280. 10.1001/jamanetworkopen.2020.2280
    1. Evangelista S. (2012). Benefits from Long-Term Treatment in Irritable Bowel Syndrome. Gastroenterol. Res. Pract. 2012, 936960. 10.1155/2012/936960
    1. Faresjö Å., Grodzinsky E., Hallert C., Timpka T. (2013). Patients with Irritable Bowel Syndrome Are More Burdened by Co-morbidity and Worry about Serious Diseases Than Healthy Controls-Eeight Years Follow-Up of IBS Patients in Primary Care. BMC public health 13, 832. 10.1186/1471-2458-13-832
    1. Fukudo S., Okumura T., Inamori M., Okuyama Y., Kanazawa M., Kamiya T., et al. (2021). Evidence-based Clinical Practice Guidelines for Irritable Bowel Syndrome 2020. J. Gastroenterol. 56 (3), 193–217. 10.1007/s00535-020-01746-z
    1. Guo Y., Niu K., Momma H., Kobayashi Y., Chujo M., Otomo A., et al. (2014). Irritable Bowel Syndrome Is Positively Related to Metabolic Syndrome: a Population-Based Cross-Sectional Study. PloS one 9 (11), e112289. 10.1371/journal.pone.0112289
    1. Gwee K. A., Gonlachanvit S., Ghoshal U. C., Chua A. S. B., Miwa H., Wu J., et al. (2019). Second Asian Consensus on Irritable Bowel Syndrome. J. Neurogastroenterol Motil. 25 (3), 343–362. 10.5056/jnm19041
    1. Hassan C., East J., Radaelli F., Spada C., Benamouzig R., Bisschops R., et al. (2019). Bowel Preparation for Colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 51 (08), 775–794. 10.1055/a-0959-0505
    1. Hsieh C. Y., Su C. C., Shao S. C., Sung S. F., Lin S. J., Kao Yang Y. H., et al. (2019). Taiwan's National Health Insurance Research Database: Past and Future. Clin. Epidemiol. 11, 349–358. 10.2147/CLEP.S196293
    1. Lacy B. E., Pimentel M., Brenner D. M., Chey W. D., Keefer L. A., Long M. D., et al. (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 116 (1), 17–44. 10.14309/ajg.0000000000001036
    1. Lee S. H., Kim K. N., Kim K. M., Joo N. S. (2016). Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome. Yonsei Med. J. 57 (1), 146–152. 10.3349/ymj.2016.57.1.146
    1. Li C. Y., Li S. C. (2015). Treatment of Irritable Bowel Syndrome in China: a Review. World J. Gastroenterol. 21 (8), 2315–2322. 10.3748/wjg.v21.i8.2315
    1. Locke G. R., 3rd, Yawn B. P., Wollan P. C., Melton L. J., 3rd, Lydick E., Talley N. J. (2004). Incidence of a Clinical Diagnosis of the Irritable Bowel Syndrome in a United States Population. Aliment. Pharmacol. Ther. 19 (9), 1025–1031. 10.1111/j.1365-2036.2004.01938.x
    1. Lovell R. M., Ford A. C. (2012). Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: a Meta-Analysis. Clin. Gastroenterol. Hepatol. 10 (7), 712–e4. 10.1016/j.cgh.2012.02.029
    1. Lu C. L., Chen C. Y., Lang H. C., Luo J. C., Wang S. S., Chang F. Y., et al. (2003). Current Patterns of Irritable Bowel Syndrome in Taiwan: the Rome II Questionnaire on a Chinese Population. Aliment. Pharmacol. Ther. 18 (11-12), 1159–1169. 10.1046/j.1365-2036.2003.01711.x
    1. Masuy I., Pannemans J., Tack J. (2020). Irritable Bowel Syndrome: Diagnosis and Management. Minerva Gastroenterol. Dietol 66 (2), 136–150. 10.23736/S1121-421X.19.02640-0
    1. Moayyedi P., Andrews C. N., MacQueen G., Korownyk C., Marsiglio M., Graff L., et al. (2019). Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol. 2 (1), 6–29. 10.1093/jcag/gwy071
    1. Pan C. H., Chang C. C., Su C. T., Tsai P. S. (2016). Trends in Irritable Bowel Syndrome Incidence Among Taiwanese Adults during 2003-2013: A Population-Based Study of Sex and Age Differences. PloS one 11 (11), e0166922. 10.1371/journal.pone.0166922
    1. Rangan V., Ballou S., Shin A., Camilleri M., Lembo A., Lembo A. (2020). Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. Gastroenterology 158 (3), 786–e1. 10.1053/j.gastro.2019.10.036
    1. Ruigómez A., Wallander M. A., Johansson S., García Rodríguez L. A. (1999). One-year Follow-Up of Newly Diagnosed Irritable Bowel Syndrome Patients. Aliment. Pharmacol. Ther. 13 (8), 1097–1102. 10.1046/j.1365-2036.1999.00576.x
    1. Ruigómez A., Wallander M. A., Johansson S., Rodríguez L. A. (2009). Irritable Bowel Syndrome and Gastroesophageal Reflux Disease in Primary Care: Is There a Link? Dig. Dis. Sci. 54 (5), 1079–1086.
    1. Sayuk G. S., Wolf R., Chang L. (2017). Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals with Diarrhea-Predominant Irritable Bowel Syndrome. Am. J. Gastroenterol. 112 (6), 892–899. 10.1038/ajg.2016.574
    1. Sibelli A., Chalder T., Everitt H., Workman P., Windgassen S., Moss-Morris R. (2016). A Systematic Review with Meta-Analysis of the Role of Anxiety and Depression in Irritable Bowel Syndrome Onset. Psychol. Med. 46 (15), 3065–3080. 10.1017/S0033291716001987
    1. Wang P. X., Deng X. R., Zhang C. H., Yuan H. J. (2020). Gut Microbiota and Metabolic Syndrome. Chin. Med. J. (Engl) 133 (7), 808–816. 10.1097/CM9.0000000000000696
    1. Wang Y. W., Chen H. H., Wu M. S., Chiu H. M. (2018). Current Status and Future challenge of Population-Based Organized Colorectal Cancer Screening: Lesson from the First Decade of Taiwanese Program. J. Formos. Med. Assoc. 117 (5), 358–364. 10.1016/j.jfma.2017.09.010
    1. Whitehead W. E., Palsson O. S., Levy R. R., Feld A. D., Turner M., Von Korff M. (2007). Comorbidity in Irritable Bowel Syndrome. Am. J. Gastroenterol. 102 (12), 2767–2776. 10.1111/j.1572-0241.2007.01540.x
    1. Yarandi S. S., Nasseri-Moghaddam S., Mostajabi P., Malekzadeh R. (2010). Overlapping Gastroesophageal Reflux Disease and Irritable Bowel Syndrome: Increased Dysfunctional Symptoms. World J. Gastroenterol. 16 (10), 1232–1238. 10.3748/wjg.v16.i9.1232
    1. Yoon J., Chow A. (2017). Comparing Chronic Condition Rates Using ICD-9 and ICD-10 in VA Patients FY2014-2016. BMC Health Serv. Res. 17 (1), 572. 10.1186/s12913-017-2504-9
    1. Zamani M., Alizadeh-Tabari S., Zamani V. (2019). Systematic Review with Meta-Analysis: the Prevalence of Anxiety and Depression in Patients with Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 50 (2), 132–143. 10.1111/apt.15325

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅